Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT3989 in Locally Advanced or Metastatic Solid Tumors
NCT04665206Phase 2Recruiting
- Sponsor
- Vivace Therapeutics
- Start
- Mar 2021
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of VT03989 in solid tumor, mesothelioma and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Vivace Therapeutics. Primary endpoints: Dose Limiting Toxicity at 21 days and Occurrence of General Toxicity at 30 months. Started Mar 2021; status: recruiting.
02
Drugs
VT03989
03
Conditions
solid tumormesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04665206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665206.